Martel A, Oberic A, Moulin A, Tieulie N, Hamedani M
Hôpital ophtalmique Jules-Gonin, 15, avenue de France, 1004 Lausanne, Suisse; Service d'ophtalmologie, hôpital Pasteur 2, CHU de Nice, 30, voie Romaine, 06000 Nice, France.
Hôpital ophtalmique Jules-Gonin, 15, avenue de France, 1004 Lausanne, Suisse.
J Fr Ophtalmol. 2018 Jun;41(6):492-506. doi: 10.1016/j.jfo.2017.11.027. Epub 2018 Jun 25.
To assess demographic, clinical, radiological, pathological features, treatment and follow-up of periocular or/and orbital amyloidosis.
We conducted an observational retrospective monocentric study from January 2004 to April 2017 in patients diagnosed with histologically proven periocular or/and orbital amyloidosis.
Six patients were included (2 females, 4 males). Mean age was 76.8 years (range 66-88 years). Mean time between first ophthalmological symptoms and diagnosis was 27 months (range 11-36 months). The main symptoms were subconjunctival infiltration (6 patients; 100%), periocular pain or discomfort (4 patients; 66.6%) and subconjunctival hemorrhage (1 patient; 16.6%). Clinical findings included ptosis (4 patients; 66.6%), keratitis (3 patients; 50%) leading to corneal perforation in one patient, and proptosis (3 patients; 50%). One-half of the patients showed bilateral involvement. AL amyloidosis was identified on immunohistochemistry in 5 patients (83.3%). One case of B cell marginal zone orbital lymphoma was diagnosed. Systemic work-up was negative for all patients. Treatment consisted of simple monitoring (1 patient; 16.6%), surgical debulking (3 patients; 50%), ptosis surgery (1 patient; 16.6%), eyelid or eyelash malposition surgery (2 patients; 33.3%) and orbital radiation beam therapy (2 patients; 33.3%). Mean follow-up was 14.6 months (range 6-36 months), and no progression nor recurrence were noted.
Periocular or/and orbital amyloidosis is rarely encountered. Diagnosis is based on pathological examination, and immunohistochemistry analysis should always be performed to guide systemic work-up. Orbital lymphoma and multiple myeloma should be ruled out if AL amyloidosis is diagnosed. Progression is slow, and surgery is the mainstay of treatment in symptomatic patients. Long-term multidisciplinary follow-up is advocated.
评估眼周或/和眼眶淀粉样变性的人口统计学、临床、放射学、病理学特征、治疗及随访情况。
我们于2004年1月至2017年4月对经组织学证实为眼周或/和眼眶淀粉样变性的患者进行了一项观察性回顾性单中心研究。
纳入6例患者(2例女性,4例男性)。平均年龄为76.8岁(范围66 - 88岁)。首次眼科症状出现至诊断的平均时间为27个月(范围11 - 36个月)。主要症状为结膜下浸润(6例患者;100%)、眼周疼痛或不适(4例患者;66.6%)以及结膜下出血(1例患者;16.6%)。临床检查发现包括上睑下垂(4例患者;66.6%)、角膜炎(3例患者;50%),其中1例患者发生角膜穿孔,以及眼球突出(3例患者;50%)。半数患者表现为双侧受累。免疫组织化学检查发现5例患者(83.3%)为AL型淀粉样变性。诊断出1例B细胞边缘区眼眶淋巴瘤。所有患者全身检查均为阴性。治疗包括单纯观察(1例患者;16.6%)、手术减瘤(3例患者;50%)、上睑下垂手术(1例患者;16.6%)、眼睑或睫毛位置异常手术(2例患者;33.3%)以及眼眶放射治疗(2例患者;33.3%)。平均随访时间为14.6个月(范围6 - 36个月),未观察到病情进展或复发。
眼周或/和眼眶淀粉样变性较为罕见。诊断基于病理检查,且应始终进行免疫组织化学分析以指导全身检查。若诊断为AL型淀粉样变性,应排除眼眶淋巴瘤和多发性骨髓瘤。病情进展缓慢,对于有症状的患者,手术是主要治疗方法。提倡进行长期多学科随访。